jeudi 21 mai 2015

Onco Actu du 21 mai 2015

1. Biologie

Novel Microfluidic Device May Shed Light on Why Cancer Cells Metastasize [GEN]

Device smushes cancer to see if it's squishy [Futurity]

2. Etiologie

Links between hay fever, asthma and prostate cancer inconclusive [NHS Choices]

3. Prévention

Well: How a Childhood Vaccine Reduces Risk of a Cancer [NY Times]

3.1 Tabac

MPs took tobacco firms' gifts before packaging vote [The Telegraph]

3.5 Prévention - UV

Don't Fry Day Reminds Us To Stay Safe In The Sun [Dr Len]

4.1 Dép., diag. & prono. - Prostate

UCSF-led Study Shows Oncotype DX® and MRI May Provide Independent Information in Favorable Risk Prostate Cancer [Genomic Health]

5. Traitements

Combining targeted cancer drugs is best when used to the max [The Institute of Cancer Research]

Study Finds Biomarker May Boost Ovarian Cancer Chemotherapy Response [MD Anderson Cancer Center]

5.12 Immunothérapies

Emerging Approaches to Cancer Immunotherapy [The New York Academy of Sciences]

5.2 Pharma

Novartis drug Afinitor® extended progression-free survival in Phase III trial in advanced gastrointestinal or lung neuroendocrine tumors [Novartis]

Johnson & Johnson Pharmaceutical Segment to Continue Driving Above-Industry Growth with Plans to File More than 10 New Products by 2019, Each with Potential to Exceed $1 Billion in Revenue [Johnson & Johnson]

J&J says will submit 10 medicines to regulators by 2019 [Reuters]

5.2.2 Pharma - Fusions & Acquisitions

Should Pfizer snap up GSK? Well, a megadeal could speed up a split [FiercePharma]

5.5.1 ASCO (général)

Industry awaits key immunotherapy results at ASCO [Pharmafile] ASCO (général) - Industriels

AVEO Oncology Announces Presentation of Final Results of Extension Study 902 and FDA Regulatory Feedback for Advancing Tivozanib in Renal Cell Carcinoma [Aveo]

OncoGenex Announces Data to be Presented at ASCO 2015 Annual Meeting [OncoGenex]

5.5.10 ASCO (hémato)

ERYTECH announces oral presentations of GRASPA® Phase III results at ASCO and EHA annual meetings [Erytech Pharma]

6. Lutte contre les cancers

Many hands make light work – the evolution of clinical trials [Cancer Research UK]

6.1 Observation

Cancer waiting time targets – simply not good enough [Cancer Research UK]

NHS fails 'thousands' cancer patients [BBC News]

NHS cancer care faces fresh scrutiny after hospitals miss key targets [The Guardian]

6.10 Politiques

Morocco joins the International Agency for Research on Cancer [ecancer - News]

6.3 Associations

Bogus Cancer Charities Are Harmful To Patients: How To Give Wisely [Forbes]

6.6 Publications

Open-access publisher sacks 31 editors amid fierce row over independence [Science]

6.8 Communication

Dana-Farber/Brigham and Women's Cancer Center launches online resource for precision cancer medicine [Dana-Farber Cancer Institute]

NanoKnife for pancreatic cancer: Why a disputed news release reflects important truths about health care news [HealthNewsReview]

6.9 Controverses

Opinion: Public Data, Private Concerns [The Scientist]